# A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

> **NCT01707407** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 32 (actual)

## Conditions studied

- Pharmacology, Clinical
- Healthy

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Ketoconazole
- **DRUG:** Fluvoxamine
- **DRUG:** Carbamazepine

## Key facts

- **NCT ID:** NCT01707407
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-01
- **Primary completion:** 2012-11-01
- **Final completion:** 2012-11-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01707407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01707407, "A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01707407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*